Explore the impact of the recent US import ban on select Apple Watch models, stemming from a blood-oxygen level detection patent clash. Dive into the legal battle with Masimo Corp, Apple’s efforts to overturn the ban, and the broader implications for the smartwatch industry in this SEO-optimized update.»
In a pivotal development, a US import ban has now been enforced on specific Apple smartwatch models, driven by a patent dispute over blood-oxygen level detection technology. Delve into the details of this ban, originating from the United States International Trade Commission’s ruling in October, and learn about Apple’s legal tussle with Masimo Corp, the pioneer of «light-based oximetry functionality.»
Apple, disputing the ITC’s decision, temporarily halted sales of Apple Watch Series 9 and Apple Watch Ultra 2 in the US last week. The ban became effective on the online Apple Store on December 21, with retail locations ceasing sales on December 24, just before the holiday season.
The patent clash traces back to a complaint filed by Masimo Corp in mid-2021, alleging Apple’s infringement on their technology and employee poaching tactics. Despite Apple’s objections, Ambassador Katherine Tai’s decision not to reverse the ITC’s determination solidified the ban on December 26, 2023. Reversing import bans lies within the president’s authority but is a rare occurrence.
As a dominant player in the smartwatch category, Apple continuously enhances fitness and health features. The recently released Apple Watch Series 9, in September, showcased heightened performance and advanced health data accessibility.
Expressing strong disagreement with the USITC decision, Apple is actively working to restore availability for the impacted models. The legal battle with Masimo, marked by a mistrial in May and counter lawsuits by Apple, unfolds against the backdrop of accusations of hindering competition.
